ARCUTIS BIOTHERAPEUTICS, INC. (ARQT): what the price requires

At today's price, ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) is priced for today's economics sustained for ~9.7 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/ARQT

Headline

FieldValue
TickerARQT
CompanyARCUTIS BIOTHERAPEUTICS, INC.
Current price$27.19/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisrevenue-multiple
EV / sales paid9.9x
Steady-state operating margin assumed36.1%
Must persist for9.7y

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 11.6% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.9 years.

Reconcile: at the x-ray's 9.3% required return this reads ~5.4 years; the models below use their own rates.

How unusual the bet is: elevated (limited comparison data)

ReferenceValue
sustained it ~9.7 years at this level16%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset18.50x1expensive
Earnings17.32x1expensive
Relative2.12x2expensive
Growth1.32x4expensive

Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.0%); the inversion above states its own rate.

Per-Model Detail (n=8)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$8.573.17xyesFCF base $0.0B, growth 25% (input: historical growth), terminal g 4.0%, WACC 9.0%, 7yr projection
DCF Exit MultipleGrowth$28.770.95xyesExit EV/EBITDA: 1119.1x / 1122.1x / 1125.1x (bear / base = today's held flat / bull), 7yr
Relative ValuationRelative$12.852.12xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$1.4718.50xyesBook value floor: BV/sh $1.47, ROE negative
Two-Stage Excess ReturnAsset$1.3220.60xyesBook value with convergence: BV/sh $1.47, ROE converges to ke (excluded from median)
Discounted Future Market CapGrowth$39.450.69xyesRev $0.4B, growth 30% (input: historical growth; tapered), Terminal P/S: 6.8x / 8.5x / 10.2x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth$15.951.70xyesMargin ramp: -1% → 12% over 7yr, rev growth 30% (input: historical growth; tapered)
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$0.012719.00xyesEBITDA $0.00B × sector EV/EBITDA 16.0x (excluded from median)
FCF YieldEarnings$1.5717.32xyesFCF $26.9M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$12.852.12xyesRevenue $0.42B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$114.6m
Interest coverage-3.0x
Share count CAGR (dilution)27.4%
Burning cashno

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

Bull Case

The counterintuitive fact about Arcutis is that a small dermatology company, still printing a loss per share, is already running at a 90.7% gross margin and generating positive cash from operations. Most companies this size are years from either milestone. ZORYVE net product revenue reached $105.4 million in Q1 2026, up 65% from a year earlier, and the company produced $2.2 million of positive operating cash flow in the quarter. That combination, a topical drug with near-90% gross margins and a business that has stopped consuming cash, is the inflection the bull case is built on: the heavy spending years are behind it, and incremental revenue now drops toward the bottom line rather than funding losses.

The engine is a single, well-protected molecule deployed across multiple formulations. ZORYVE revenue in the quarter split across roflumilast cream 0.3%, topical foam 0.3%, and cream 0.15%, each addressing a different dermatologic indication from one underlying compound. The company holds "our own intellectual property portfolio around topical uses of roflumilast", which is what lets it expand into new skin conditions without inventing a new drug each time. Taking one validated mechanism and stretching it across indications is the same capital-efficient playbook the best specialty-pharma names use; each new label is incremental revenue on an already-built commercial infrastructure.

The demand trajectory and the guidance frame the runway. The company continues to take share of branded non-steroidal topical treatments and maintained full-year 2026 revenue guidance of $480 million to $495 million, implying 26% to 30% growth over the prior year. With $224 million of liquid assets on hand, the business is funded to keep expanding the label without leaning on the equity market the way it once did. The bull case is straightforward: a high-margin franchise that has just crossed the line from cash consumer to cash generator, with a protected molecule, a widening set of indications, and a clear growth target.

Bear Case

The honest framing of the risk is concentration: this is a one-drug company, and roflumilast is the whole story. Every formulation, every indication, every dollar of the $105 million quarter traces back to a single molecule. That is efficient when it works and fragile when it does not. A safety signal, a formulary exclusion by a large payer, a generic challenge to the patent estate, or a competitor launching a better non-steroidal topical would not dent one product line; it would threaten the entire revenue base. The peer cohort, mid-cap specialty biotechs, is littered with companies whose single asset stalled, and the market prices single-asset names with a permanent discount for exactly this reason.

The demand picture is not as linear as the year-over-year growth suggests. Revenue fell 17% from the prior quarter, which management attributes to typical first-quarter seasonality, but a sequential decline of that size is a reminder that prescription demand for a branded topical is not a smooth subscription stream. The company still reported a loss of $0.09 per share for the quarter, missing estimates, so the profitability the bull case leans on is operating-cash-flow positive, not yet earnings positive. The gap between positive cash flow and a per-share loss is non-cash, but it is also where the dilution lives.

Dilution is the structural cost a holder has to weigh. The share count has grown at roughly 26% a year over recent history, the price every shareholder paid for the company reaching commercial scale without a profit. The valuation makes that history expensive going forward. At about $26 (June 27, 2026) a share, no family of valuation method reaches the price: the asset and earnings-power approaches land near book value of $1.47 a share, the peer revenue-multiple lands near $13, and even the forward-growth methods top out around the current price only by crediting years of near-flawless execution. Inverted, the price requires the business to eventually earn an operating margin near 36% and grow at its ceiling for nine years. The drug is real and the margins are excellent, but the price is underwriting a long, uninterrupted run for a company whose entire fortune rests on one compound.

Valuation

Because Arcutis is only just crossing into operating profitability, the price is set against its sales rather than its earnings. At about $26 a share, roughly 9 times revenue, the price implies the business eventually earns an operating margin near 36% and grows revenue at its self-funding ceiling for about nine years. Keep those figures approximate; they are one solve under fixed assumptions. The plain reading is that the price is paying today for a level of mature profitability the company has not yet demonstrated, on a timeline of nearly a decade, a pace only about 23% of comparable fast-growers have historically sustained.

The methods scatter widely, which is the signature of a company valued on its future rather than its present. The asset-value family lands near a book value of $1.47 a share because the company has little tangible equity. The earnings-power family is effectively meaningless while operating income hovers near breakeven. The peer revenue-multiple family, applying a sector price-to-sales near 4 times, lands around $13. Only the growth-and-margin-trajectory methods reach toward the price, and they do so by assuming the margin ramps and the growth continues. When no backward-looking family reaches the price and only forward-growth methods approach it, the price is a bet beyond what any standard frame supports, an optionality premium on the label-expansion story.

The balance sheet is the reassuring part: about $224 million of liquid assets and a business now generating rather than consuming cash, so the usual single-product-biotech fear of running out of money has receded. What the cash position does not remove is the execution and concentration risk the multiple embeds. The decisive question the valuation poses is whether a 90%-gross-margin franchise can convert its operating-cash-flow inflection into the mature 36% operating margin the price assumes, across enough indications and enough years to grow into 9 times sales before the patent clock or a competitor intervenes.

Catalysts

The first quarter of 2026 showed the franchise scaling and the economics improving. ZORYVE net product revenue was $105.4 million, up 65% year over year, with a gross margin of 90.7% and $2.2 million of positive operating cash flow. Revenue was down 17% sequentially on typical first-quarter seasonality, and the company reported a loss of $0.09 per share. The mix spanned roflumilast cream 0.3% at $32.7 million, topical foam 0.3% at $49.6 million, and cream 0.15% at $21.7 million.

The forward catalysts are guidance delivery and label expansion. Arcutis maintained full-year 2026 revenue guidance of $480 million to $495 million, implying 26% to 30% growth, and continues to take share of branded non-steroidal topical treatments. The metrics to watch over the next several quarters are whether quarterly revenue resumes its sequential climb after the seasonal dip, whether the operating-cash-flow inflection turns into reported profitability, and whether new indications for roflumilast broaden the addressable market. Each is a direct test of the multi-year, high-margin trajectory the price is paying for.

Peer Cohorts (Per Segment, With Filing Citations)

Arcutis Biotherapeutics (single segment) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q1 2026 results, May 2026 · FY2025 10-K · company financials

View the full interactive ARQT report on boothcheck